These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9716289)

  • 21. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998.
    Sahm DF; Jones ME; Hickey ML; Diakun DR; Mani SV; Thornsberry C
    J Antimicrob Chemother; 2000 Apr; 45(4):457-66. PubMed ID: 10747822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).
    Sader HS; Gales AC; Granacher TD; Pfaller MA; Jones RN;
    Braz J Infect Dis; 2000 Oct; 4(5):245-54. PubMed ID: 11063556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
    Sahm DF; Brown NP; Thornsberry C; Jones ME
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):16-24. PubMed ID: 18931467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme.
    Reynolds R; Shackcloth J; Felmingham D; MacGowan A;
    J Antimicrob Chemother; 2003 Dec; 52(6):925-30. PubMed ID: 14585864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007.
    Morrissey I; Maher K; Williams L; Shackcloth J; Felmingham D; Reynolds R;
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 2():ii97-103. PubMed ID: 18819984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Finland.
    Manninen R; Huovinen P; Nissinen A
    J Antimicrob Chemother; 1997 Sep; 40(3):387-92. PubMed ID: 9338492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated in the UK during the 1995-1996 cold season.
    Felmingham D; Robbins MJ; Tesfaslasie Y; Harding I; Shrimpton S; Grüneberg RN
    J Antimicrob Chemother; 1998 Mar; 41(3):411-5. PubMed ID: 9578171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project.
    Schito GC; Debbia EA; Marchese A
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():3-9. PubMed ID: 10997593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM; Suter M; Borsos S
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.
    Thornsberry C; Jones ME; Hickey ML; Mauriz Y; Kahn J; Sahm DF
    J Antimicrob Chemother; 1999 Dec; 44(6):749-59. PubMed ID: 10590275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 and 2013-14 in China.
    Hu F; Zhu D; Wang F; Morrissey I; Wang J; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i33-43. PubMed ID: 27048581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections.
    Hoban D; Felmingham D
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():49-59. PubMed ID: 12239228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN; Fritsche TR; Sader HS; Stilwell MG
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of telithromycin against respiratory tract pathogens in comparison with other antimicrobial agents.
    Ling TK; Lee CC
    Chemotherapy; 2005 Jul; 51(4):182-5. PubMed ID: 15980628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
    Sun H; Chen L; Chen X; Jia X; Li N; Liu W; Tong H; Xiang R; Zhang F; Zhao H; Zhang J; Xu Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jan; 39(1):30-7. PubMed ID: 26792053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: the BSAC Respiratory Resistance Surveillance Programme.
    Reynolds R; Shackcloth J; Felmingham D; MacGowan A;
    J Antimicrob Chemother; 2003 Dec; 52(6):931-43. PubMed ID: 14585865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical resistance encountered in the respiratory surveillance program (RESP) study: a review of the implications for the treatment of community-acquired respiratory tract infections.
    Ehrhardt AF; Russo R
    Am J Med; 2001 Dec; 111 Suppl 9A():30S-35S discussion 36S-38S. PubMed ID: 11755441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.